Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 1.44B |
| Revenue (ttm) | 54.03M |
| Net Income (ttm) | -412.78M |
| Shares Out | 58.59M |
| EPS (ttm) | -7.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 350,699 |
| Open | 24.55 |
| Previous Close | 24.43 |
| Day's Range | 24.50 - 25.34 |
| 52-Week Range | 22.24 - 46.00 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 38.88 (+58.56%) |
| Earnings Date | Apr 29, 2026 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price target is $38.88, which is an increase of 58.56% from the latest price.
News
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wi...
PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake. With physicians identifying up to one-third of ...
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming mo...
Agios Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Mitapivat’s launch in thalassemia is off to a strong start, with expansion into sickle cell disease and other indications underway. Regulatory updates and key data readouts are expected throughout the year, while commercial focus remains on the U.S. market and broadening patient access.
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty compan...
Agios Pharmaceuticals Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw robust PYRUKYND revenue growth and the successful US launch of ACTIVASE for thalassemia, with strong early demand and physician engagement. The company ended 2025 with $1.2B in cash and expects continued growth and key pipeline catalysts in 2026.
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full year AQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approval Compan...
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit...
Agios Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
A major growth phase is underway, driven by the U.S. launch of Aqvesme for thalassemia and expansion of the PK activator franchise into new indications. The pipeline targets over $10 billion in global market potential by 2030, with disciplined financial management and key clinical milestones expected in 2024.
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of ...
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Agios today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat
Shares of Agios Pharmaceuticals surged nearly 15% in premarket trading on Wednesday after the US Food and Drug Administration approved an expanded use of its drug mitapivat, strengthening investor opt...
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder...
Agios Pharmaceuticals Transcript: FDA Announcement
Mitapivat (Aqneusa) received FDA approval as the first oral therapy for anemia in adults with alpha or beta thalassemia, supported by robust phase 3 data. Launch is set for late January, with a REMS program and initial focus on transfusion-dependent patients.
U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemi...
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia
Why Is Agios Pharmaceuticals Stock Sinking Today?
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.
Agios Pharma reports mixed results in late-stage study for sickle cell disease drug
Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction...
Agios Pharmaceuticals Transcript: Study Result
The phase III RISE UP trial showed mitapivat significantly improved hemoglobin in 40.6% of sickle cell disease patients, with robust reductions in pain crises and hospitalizations among responders, and a favorable safety profile. The company plans to seek FDA approval following a pre-SNDA meeting in 2026.
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did n...
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit...
Agios Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 net revenue grew 44% year-over-year to $12.9 million, driven by PYRUKYND's commercial momentum and global regulatory progress. Strong cash reserves support upcoming U.S. launches and pipeline advancement, with key data readouts and regulatory milestones expected by year end.
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
$12.9 million in third quarter PYRUKYND® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassem...
Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia
AMSTERDAM--(BUSINESS WIRE)-- #biopharma--Avanzanite's Partner Agios Pharmaceuticals Announces Regulatory Update.
Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
Agios today announced that the CHMP has adopted a positive opinion for the new indication for PYRUKYND in adults for anemia associated with thalassemia